HEALEY ALS Platform Trials

GW joins a nationwide network of research centers in the Northeast ALS (NEALS) Consortium who are partnering with the Sean M HEALEY & AMG Center to conduct the first ALS platform trial. The platform trial is designed in a way that allows for testing multiple drugs simultaneously while reducing the amount of patients that receive placebo. The trail operates under a master protocol which outlines standard procedures that all drug regimens follow. Each drug that is being tested has its own regimen, which has a sub-protocol (under the master) that outlines procedures for that specific drug. Follow this link for more information on the platform trials.

Active Regimens:

Regimen F: ABBV-CLS-7262, follow this link for more information on Regimen F.

Regimens Closed to Enrollment: 

Regimen E, Trehalose 

Soon to be activated: 

Regimen G: DNL 343, Follow this link for more information on Regimen G.

Regimen E Expanded Access Program: This trial is designed for patients not eligible for the other regimens OR who previously completed the Regimen E double blinded trial. 

If you are interested or would like to learn more, please do not hesitate to reach out to our study coordinator, Grace Johnson at 202-741-2181 or gjohnson@mfa.gwu.edu.


Sean M Healey & AMG Center for ALS at Massachusetts General Hospital
Principal Investigator(s)
Dr. Elham Bayat, Dr. Henry Kaminski
Contact Phone Number
Request Information
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.